Juno Therapeutics soars in Nasdaq debut – CNBC
CNBC |
Juno Therapeutics soars in Nasdaq debut
CNBC Juno Therapeutics soared in its Nasdaq debut Friday, after pricing above its expected range. CEO Hans Bishop told CNBC he thinks investors are generally optimistic about immunotherapy, as well as the biopharmaceutical company's cancer treatments in … Juno Therapeutics (Nasdaq: JUNO) to Ring The Nasdaq Stock Market Opening … Photo Release — Nasdaq Welcomes Juno Therapeutics (Nasdaq: JUNO) to The … Photo Release — Nasdaq Welcomes Juno Therapeutics JUNO to The Nasdaq … |
